Blocking inhibitory immune checkpoint proteins like PD-1, PD-L1, and CTLA-4 with monoclonal antibodies has revolutionized cancer treatment by counteracting cancer cells’ evasion of immune responses and restoring T cell function (32). This evidence concerns the gene CTLA4 and cancer.